EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Studybenzinga.comEyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Marketchartmill.comEyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid financial setbacks.
Breakout Momentum Plays You May Not Know AboutMomentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.
These stocks are moving in today's pre-market sessionchartmill.comWondering what's happening in Wednesday's pre-market session? Find an overview in this article.
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Lossbenzinga.comEyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.
